Canine Glomerular Disease: Diagnosis and Management

Canine glomerular disease refers to disorders that damage the glomerular capillary wall, causing pathologic protein loss into urine and potentially progressing to renal failure. For veterinarians, the diagnostic challenge is distinguishing glomerular proteinuria from other kidney diseases, and the management goal is reducing proteinuria while preserving renal function. This article reviews pathophysiology, diagnostic workup using urine protein:creatinine ratio and biopsy, and therapeutic strategies based on current consensus recommendations from the Journal of Veterinary Internal Medicine.

At a Glance

Pathophysiology of Glomerular Disease in Dogs

Glomerular disease involves damage to the glomerular capillary wall, which normally restricts passage of large plasma proteins into urine. Injury to endothelial cells, glomerular basement membrane, or podocytes increases permeability, leading to proteinuria. The Merck Veterinary Manual provides an overview of kidney structure and function relevant to understanding these disease processes. The World Organisation for Animal Health addresses animal health and welfare considerations for chronic disease management, including renal conditions.

Underlying causes are diverse and include immune-complex deposition from systemic lupus erythematosus, chronic infections, or neoplasia. Amyloidosis involves deposition of amyloid fibrils in glomeruli, causing progressive damage. Hereditary nephropathies, such as those seen in certain breeds, result from genetic defects in glomerular structural proteins. The glomerular lesions trigger a cascade of events including activation of the renin-angiotensin-aldosterone system, intraglomerular hypertension, and tubulointerstitial inflammation, which further accelerate kidney damage.

Proteinuria itself is nephrotoxic. Filtered proteins accumulate in tubular epithelial cells, causing inflammation, fibrosis, and tubular atrophy. This tubulointerstitial damage correlates more strongly with progression to renal failure than the original glomerular lesion. Understanding this pathophysiology guides therapeutic decisions aimed at reducing proteinuria and preserving renal function.

Diagnostic Workup for Suspected Glomerular Disease

Urine Protein:Creatinine Ratio

The UPC ratio is the cornerstone for quantifying proteinuria in dogs. The consensus recommendations for the diagnostic investigation of dogs with suspected glomerular disease, published in the Journal of Veterinary Internal Medicine, provide detailed guidance on interpreting UPC results. A UPC ratio greater than 0.5 in a dog with inactive urine sediment is consistent with glomerular proteinuria. Samples should be collected by cystocentesis or midstream free catch from a fasted patient to minimize variability.

Pre-renal causes of proteinuria include hemoconcentration, fever, and exercise. Post-renal causes include urinary tract infection, urolithiasis, and neoplasia. These must be ruled out before attributing proteinuria to glomerular disease. Serial UPC measurements are essential for monitoring response to therapy and disease progression. A single measurement may not reflect the full extent of protein loss due to daily variation.

Serum Biochemistry and Blood Pressure

A complete serum biochemistry panel should include albumin, total protein, cholesterol, blood urea nitrogen, and creatinine. Hypoalbuminemia is a hallmark of significant glomerular protein loss. Hypercholesterolemia is common due to altered lipid metabolism from hepatic lipoprotein synthesis. Azotemia indicates reduced glomerular filtration rate and may be present in advanced disease.

Systemic hypertension is a frequent complication of glomerular disease and should be measured using Doppler or oscillometric methods. The Merck Veterinary Manual discusses the relationship between hypertension and kidney disease in dogs. Hypertension results from activation of the renin-angiotensin-aldosterone system, sodium retention, and reduced renal function. Persistent hypertension further damages glomeruli and accelerates disease progression.

Renal Biopsy

Renal biopsy is indicated when the diagnosis remains uncertain after non-invasive testing, or when histopathology is required to guide immunosuppressive therapy. The consensus recommendations for immunosuppressive treatment of dogs with glomerular disease based on established pathology, published in the Journal of Veterinary Internal Medicine, emphasize that biopsy results directly inform the choice of immunosuppressive agents.

Biopsy should be performed by an experienced clinician using ultrasound guidance. Samples must be evaluated by light microscopy, immunofluorescence, and electron microscopy to identify the specific glomerular lesion. Light microscopy reveals patterns such as membranous glomerulonephritis, membranoproliferative glomerulonephritis, or amyloid deposition. Immunofluorescence identifies immune complex deposition patterns. Electron microscopy provides ultrastructural details of basement membrane and podocyte damage.

Biopsy is not recommended in all cases. Contraindications include uncontrolled hypertension, coagulopathy, severe azotemia, and patient instability. When amyloidosis is strongly suspected based on breed predisposition and clinical findings, biopsy may be deferred due to the risk of hemorrhage and the limited therapeutic options.

Urinary Biomarkers

Urinary biomarkers of kidney disease in dogs and cats are an area of active research, as noted in the Veterinary Clinics of North America. Biomarkers such as urinary albumin, retinol-binding protein, and neutrophil gelatinase-associated lipocalin may improve early detection and monitoring of glomerular disease. These markers can detect tubular damage before proteinuria becomes apparent. However, their routine clinical use is not yet established, and UPC ratio remains the standard for quantifying proteinuria.

Therapeutic Strategies for Glomerular Disease

Antiproteinuric Therapy

Reducing proteinuria is the primary therapeutic target. Angiotensin-converting enzyme inhibitors such as enalapril or benazepril are first-line agents. Angiotensin receptor blockers like telmisartan are alternatives. The consensus recommendations for standard therapy of glomerular disease in dogs, published in the Journal of Veterinary Internal Medicine, outline the evidence base for these agents.

ACEi and ARB reduce glomerular capillary pressure by dilating efferent arterioles, decreasing intraglomerular hypertension and protein filtration. They also have anti-inflammatory and antifibrotic effects independent of blood pressure reduction. The goal is to reduce the UPC ratio to below 0.5 or by at least 50% from baseline. Blood pressure and renal function must be monitored during therapy, as these drugs can cause hypotension and acute kidney injury in volume-depleted patients.

Dose adjustments may be necessary based on response and adverse effects. If proteinuria persists despite maximum tolerated doses of ACEi, adding an ARB may provide additional benefit. Combination therapy should be used cautiously with close monitoring of blood pressure and renal function.

Dietary Management

Dietary protein restriction is recommended for dogs with chronic kidney disease and proteinuria. The management of proteinuria in dogs and cats with chronic kidney disease, as reviewed in the Veterinary Clinics of North America, supports dietary modification as part of a multimodal approach. A diet with moderate protein restriction, but not deficiency, reduces the workload on damaged glomeruli and decreases protein filtration.

Omega-3 fatty acid supplementation may reduce glomerular hypertension and inflammation. These fatty acids compete with arachidonic acid for cyclooxygenase and lipoxygenase pathways, producing less inflammatory eicosanoids. Phosphorus restriction is also important if azotemia is present, as hyperphosphatemia accelerates renal disease progression.

Commercial renal diets are formulated with these principles in mind. They provide restricted but adequate protein, reduced phosphorus, and added omega-3 fatty acids. Owner compliance is critical, as homemade diets may be nutritionally unbalanced. Consultation with a veterinary nutritionist is recommended for homemade diet formulation.

Immunosuppressive Therapy

Immunosuppressive therapy is reserved for dogs with biopsy-proven immune-mediated glomerulonephritis. The consensus recommendations for immunosuppressive treatment of dogs with glomerular disease based on established pathology, published in the Journal of Veterinary Internal Medicine, provide specific protocols based on histopathologic pattern.

Membranous glomerulonephritis, characterized by subepithelial immune complex deposition, may respond to mycophenolate mofetil or cyclosporine. Membranoproliferative glomerulonephritis, with mesangial proliferation and basement membrane thickening, may require more aggressive immunosuppression. Corticosteroids are used cautiously due to their protein catabolic effects and potential to worsen proteinuria.

Immunosuppression carries risks of infection, bone marrow suppression, and gastrointestinal upset. Patients must be monitored closely for adverse effects. Treatment should only be initiated after careful patient evaluation and with owner consent. The decision to use immunosuppressive therapy should be based on histopathology, clinical severity, and the likelihood of response.

Management of Nephrotic Syndrome

Nephrotic syndrome, characterized by severe proteinuria, hypoalbuminemia, edema, and ascites, requires aggressive management. The clinical features and evidence-based treatment considerations for nephrotic syndrome in dogs are discussed in Topics in Companion Animal Medicine. Hospitalization and intensive monitoring are often necessary.

Diuretics such as furosemide may be used cautiously for edema, but can worsen azotemia by reducing intravascular volume. Loop diuretics should be started at low doses and titrated based on response. Spironolactone, a potassium-sparing diuretic, may be added for refractory edema but carries risk of hyperkalemia.

Antithrombotic therapy is often considered due to the risk of thromboembolism. Dogs with nephrotic syndrome lose antithrombin III in urine, creating a hypercoagulable state. Low-dose aspirin may reduce platelet aggregation, but evidence for its efficacy is limited. The decision to use antithrombotic therapy should be individualized based on risk factors and owner consent.

Management of Hypertension

Systemic hypertension in dogs with glomerular disease should be treated to reduce further renal damage and prevent target organ damage. The Merck Veterinary Manual discusses the relationship between hypertension and kidney disease in dogs. ACEi and ARB are first-line antihypertensive agents in these patients due to their renoprotective effects.

If blood pressure remains elevated despite maximum doses of ACEi or ARB, additional antihypertensive agents may be needed. Amlodipine, a calcium channel blocker, is commonly added. It dilates afferent arterioles, reducing systemic blood pressure without significantly affecting glomerular pressure. Beta-blockers and diuretics may be used in refractory cases.

Blood pressure should be measured at each recheck visit using standardized protocols. Multiple measurements over several visits may be needed to confirm hypertension. Target blood pressure is less than 140 mmHg systolic, but individual patient factors may influence goals.

Monitoring and Prognosis

Regular monitoring includes serial UPC ratios, serum albumin, creatinine, BUN, and blood pressure. The frequency of monitoring depends on disease severity and response to therapy. Stable patients may be rechecked every 1 to 3 months. Unstable patients or those with nephrotic syndrome may require weekly or biweekly monitoring.

UPC ratio should be measured at each visit to assess response to antiproteinuric therapy. A reduction of at least 50% from baseline or to below 0.5 is considered a good response. If proteinuria persists or worsens, the treatment plan should be reassessed. Serum albumin levels reflect the severity of protein loss and may improve with successful therapy.

Creatinine and BUN monitor renal function. Worsening azotemia may indicate disease progression, adverse effects of therapy, or concurrent conditions such as dehydration. Blood pressure should be measured at each visit to ensure adequate control and detect hypotension from ACEi or ARB therapy.

Prognosis varies widely based on the underlying cause, severity of proteinuria, and response to treatment. Dogs with immune-mediated glomerulonephritis that responds to immunosuppression may have a good outcome. Dogs with amyloidosis generally have a poor prognosis, with median survival times of less than 6 months. Dogs that develop end-stage kidney disease have a poor prognosis regardless of the underlying cause.

Common Failure Patterns in Management

Limitations and Safety Considerations

Diagnostic limitations include the inability to identify the underlying cause in many cases. Idiopathic glomerulonephritis is a diagnosis of exclusion after ruling out infectious, inflammatory, and neoplastic causes. Renal biopsy carries risks of hemorrhage, hematoma formation, and sampling error. Not all veterinary practices have access to the specialized pathology services required for complete biopsy evaluation.

Therapeutic limitations include the lack of specific treatments for many forms of glomerular disease. Amyloidosis has no proven therapy in dogs, and treatment is supportive. Immunosuppressive therapy may not be effective in all cases of immune-mediated glomerulonephritis. Owner compliance with dietary modification and medication administration is essential for success.

Safety considerations include the risk of adverse effects from ACEi, ARB, and immunosuppressive agents. ACEi can cause hypotension, acute kidney injury, and hyperkalemia. ARB have similar risks. Immunosuppressive agents increase the risk of infection and may cause bone marrow suppression. Diuretics can cause electrolyte imbalances and worsen azotemia. All therapies should be used with caution and appropriate monitoring.

Professional Escalation Criteria

Veterinarians should consider referral to a veterinary internist or nephrologist in the following situations:

• Persistent proteinuria despite maximum tolerated doses of ACEi and ARB
• Worsening azotemia without identifiable cause
• Nephrotic syndrome requiring intensive management
• Need for renal biopsy to guide therapy
• Suspected hereditary nephropathy requiring genetic testing
• Refractory hypertension despite multiple antihypertensive agents
• Complications of therapy such as severe adverse effects

Referral centers have access to advanced diagnostic tools including renal biopsy with specialized pathology, genetic testing for hereditary nephropathies, and hemodialysis for acute kidney injury. They also have experience managing complex cases and can provide owner education and support.

Practical Decision Framework for Managing Canine Glomerular Disease: A Stepwise Approach Based on Clinical Severity and Response

Managing canine glomerular disease requires a structured decision framework that accounts for disease severity, response to initial therapy, and the presence of complications. Without a systematic approach, clinicians may delay appropriate interventions or escalate therapy unnecessarily. This section provides a practical decision framework organized by clinical severity, a record system for tracking key parameters, troubleshooting methods for common management challenges, and a comparison of antiproteinuric drug classes to guide therapeutic choices.

Clinical Severity Staging and Corresponding Management Pathways

The first step in applying a decision framework is to stage the patient based on proteinuria severity, serum albumin concentration, and the presence of complications such as edema, ascites, or hypertension. The consensus recommendations for standard therapy of glomerular disease in dogs, published in the Journal of Veterinary Internal Medicine, provide a foundation for staging, though specific numeric thresholds for severity categories are not universally defined. The following framework uses commonly accepted clinical cutoffs derived from published consensus and clinical experience.

Stage 1: Mild Proteinuria (UPC 0.5 to 1.5, Normal Albumin, No Azotemia)

Patients in this stage have early glomerular disease without significant protein loss or renal dysfunction. The primary goal is to slow progression and prevent worsening of proteinuria.

Management steps:

1. Confirm persistent proteinuria with at least two UPC measurements 2 to 4 weeks apart, ruling out pre-renal and post-renal causes.
2. Measure blood pressure using Doppler or oscillometric methods. If systolic pressure exceeds 140 mmHg, initiate antihypertensive therapy.
3. Start an angiotensin-converting enzyme inhibitor (ACEi) such as enalapril at 0.5 mg/kg orally every 12 to 24 hours, or benazepril at 0.25 to 0.5 mg/kg orally every 24 hours. The Merck Veterinary Manual provides general dosing guidelines for these medications.
4. Recheck UPC, serum creatinine, and blood pressure 2 to 4 weeks after starting therapy.
5. If UPC decreases by less than 50% or remains above 0.5, consider increasing the ACEi dose to the maximum tolerated level, typically 1.0 mg/kg every 12 hours for enalapril.
6. If proteinuria persists despite maximum ACEi dose, add an angiotensin receptor blocker (ARB) such as telmisartan at 1.0 mg/kg orally every 24 hours. Monitor blood pressure closely for hypotension.

Dietary modification is recommended at this stage. Transition the patient to a commercial renal diet with moderate protein restriction, reduced phosphorus, and added omega-3 fatty acids. The management of proteinuria in dogs and cats with chronic kidney disease, reviewed in the Veterinary Clinics of North America, supports dietary intervention as part of a multimodal approach.

Stage 2: Moderate Proteinuria (UPC 1.5 to 3.5, Mild Hypoalbuminemia 2.0 to 2.5 g/dL, No Edema)

Patients in this stage have significant protein loss but have not yet developed nephrotic syndrome. The risk of progression to renal failure is higher, and more aggressive intervention is warranted.

Management steps:

1. Initiate ACEi therapy at standard doses and titrate to maximum tolerated dose within 2 to 4 weeks.
2. Add an ARB if proteinuria does not decrease by at least 50% or remains above 1.0 after ACEi optimization.
3. Measure blood pressure at each visit. If systolic pressure exceeds 150 mmHg despite ACEi and ARB, add amlodipine at 0.1 to 0.25 mg/kg orally every 24 hours, titrating up to 0.5 mg/kg as needed.
4. Consider renal biopsy if the underlying cause is uncertain or if immunosuppressive therapy is being considered. The consensus recommendations for the diagnostic investigation of dogs with suspected glomerular disease, published in the Journal of Veterinary Internal Medicine, outline indications for biopsy.
5. If biopsy reveals immune-mediated glomerulonephritis, discuss immunosuppressive therapy with the owner. The consensus recommendations for immunosuppressive treatment of dogs with glomerular disease based on established pathology, published in the Journal of Veterinary Internal Medicine, provide specific protocols.
6. Monitor serum albumin, UPC, creatinine, and blood pressure every 4 to 6 weeks until stable, then every 2 to 3 months.

Stage 3: Severe Proteinuria (UPC Greater than 3.5, Hypoalbuminemia Less than 2.0 g/dL, With or Without Edema or Ascites)

These patients have nephrotic syndrome or are at high risk of developing it. Hospitalization is often required for initial stabilization.

Management steps:

1. Hospitalize the patient for intravenous fluid therapy if dehydrated, but avoid overhydration. Use balanced crystalloid solutions at maintenance rates.
2. Start ACEi therapy at low doses (0.25 mg/kg every 12 to 24 hours) and titrate slowly to avoid hypotension. Monitor blood pressure and renal function daily.
3. Add an ARB if proteinuria does not improve within 1 to 2 weeks.
4. Manage edema with cautious diuretic therapy. Furosemide at 1 to 2 mg/kg intravenously or orally every 12 to 24 hours may be used, but monitor for worsening azotemia. The clinical features and evidence-based treatment considerations for nephrotic syndrome in dogs, discussed in Topics in Companion Animal Medicine, emphasize careful diuretic use.
5. Consider antithrombotic therapy. Low-dose aspirin at 0.5 to 1.0 mg/kg orally every 24 hours may reduce thromboembolic risk, though evidence is limited. Discuss risks and benefits with the owner.
6. Perform renal biopsy if the patient is stable and the diagnosis is uncertain. Biopsy is contraindicated in unstable patients or those with uncontrolled hypertension or coagulopathy.
7. If biopsy confirms immune-mediated disease, initiate immunosuppressive therapy as per consensus recommendations.
8. Monitor UPC, serum albumin, creatinine, and blood pressure daily during hospitalization, then weekly after discharge until stable.

Stage 4: End-Stage Kidney Disease (Azotemia with Creatinine Greater than 4.0 mg/dL, UPC Variable)

Patients with advanced renal failure have limited therapeutic options. The focus shifts to supportive care and quality of life.

Management steps:

1. Continue ACEi or ARB therapy if tolerated, but reduce doses if hypotension or worsening azotemia occurs.
2. Manage uremia with dietary protein restriction, phosphate binders, and antiemetics as needed.
3. Treat hypertension with amlodipine if ACEi or ARB are not tolerated.
4. Discuss prognosis with the owner. Median survival times are short, and euthanasia may be considered when quality of life declines.
5. Refer to a veterinary internist for consideration of hemodialysis if appropriate and available.

Record System for Tracking Key Parameters

A standardized record system is essential for monitoring disease progression and treatment response. The following table provides a template for tracking key parameters at each visit. This system allows the clinician to identify trends and adjust therapy promptly.

Instructions for use:

• Record UPC at each visit. A decrease of at least 50% from baseline or to below 0.5 indicates a good response.
• Serum albumin reflects the severity of protein loss. Improvement suggests effective antiproteinuric therapy.
• Creatinine and BUN monitor renal function. A sustained increase of more than 0.5 mg/dL in creatinine may indicate disease progression or adverse drug effects.
• Blood pressure should be measured using a standardized protocol. Multiple readings over several minutes are averaged.
• Medications and doses should be recorded to track changes and ensure compliance.
• Notes should include any adverse effects, owner concerns, or changes in clinical status.

Troubleshooting Methods for Common Management Challenges

Even with a structured framework, clinicians encounter challenges that require troubleshooting. The following methods address common failure patterns.

Challenge 1: Persistent Proteinuria Despite Maximum ACEi and ARB Therapy

If UPC remains above 0.5 or has not decreased by at least 50% after 4 to 8 weeks of maximum tolerated ACEi and ARB therapy, consider the following:

1. Verify owner compliance. Ask about missed doses or difficulty administering medications.
2. Recheck blood pressure. Uncontrolled hypertension can worsen proteinuria. If systolic pressure exceeds 140 mmHg, add amlodipine.
3. Rule out concurrent conditions that cause proteinuria, such as urinary tract infection, hyperadrenocorticism, or diabetes mellitus. Perform urine culture, ACTH stimulation test, or blood glucose measurement as indicated.
4. Consider dietary indiscretion. Some dogs on renal diets may still receive high-protein treats or table food. Review the diet history with the owner.
5. If all above are ruled out, consider renal biopsy to identify the specific glomerular lesion. Some forms of glomerulonephritis may require immunosuppressive therapy for adequate proteinuria reduction.

Challenge 2: Worsening Azotemia During ACEi or ARB Therapy

A rise in creatinine of more than 0.5 mg/dL within 2 to 4 weeks of starting ACEi or ARB therapy requires evaluation.

1. Assess hydration status. Dehydration from vomiting, diarrhea, or reduced water intake can worsen azotemia. Provide subcutaneous or intravenous fluids if needed.
2. Reduce the ACEi or ARB dose by 25% to 50% and recheck creatinine in 5 to 7 days.
3. If azotemia persists despite dose reduction, temporarily discontinue the drug and recheck creatinine in 3 to 5 days.
4. If creatinine returns to baseline after drug discontinuation, consider restarting at a lower dose or switching to the other drug class.
5. If azotemia does not improve after drug discontinuation, investigate other causes such as disease progression, urinary obstruction, or concurrent nephrotoxic drug use.

Challenge 3: Refractory Edema Despite Diuretic Therapy

Edema that does not resolve with furosemide at 2 mg/kg every 12 hours requires a systematic approach.

1. Assess dietary sodium intake. Commercial renal diets are low in sodium, but some owners may add salt to food. Review the diet history.
2. Increase furosemide dose to 3 to 4 mg/kg every 12 hours, but monitor for worsening azotemia and electrolyte imbalances.
3. Add spironolactone at 1 to 2 mg/kg orally every 12 hours. This potassium-sparing diuretic may provide additive effect. Monitor potassium levels closely.
4. If edema persists, consider hospitalization for intravenous furosemide infusion or addition of a thiazide diuretic such as hydrochlorothiazide.
5. Re-evaluate the underlying disease. Worsening glomerular disease may require more aggressive antiproteinuric or immunosuppressive therapy.

Challenge 4: Hypertension Refractory to ACEi, ARB, and Amlodipine

If systolic blood pressure remains above 150 mmHg despite maximum doses of three antihypertensive agents, consider the following:

1. Verify measurement technique. Use a properly sized cuff and allow the patient to acclimate to the environment. Repeat measurements over several visits.
2. Rule out secondary causes of hypertension such as hyperadrenocorticism, pheochromocytoma, or renal artery stenosis. Perform appropriate diagnostic tests.
3. Add a beta-blocker such as atenolol at 0.5 to 1.0 mg/kg orally every 12 to 24 hours, or a vasodilator such as hydralazine at 0.5 to 2.0 mg/kg orally every 12 hours.
4. Refer to a veterinary internist for advanced management. Refractory hypertension carries a high risk of target organ damage including retinopathy, encephalopathy, and cardiovascular events.

Comparison of Antiproteinuric Drug Classes

Choosing between ACEi and ARB, or using them in combination, requires understanding their differences. The following table compares these drug classes for use in canine glomerular disease.

Clinical decision points:

• Start with an ACEi as first-line therapy due to lower cost and extensive clinical experience.
• Switch to an ARB if the patient develops adverse effects to ACEi, such as cough or hyperkalemia.
• Add an ARB to ACEi if proteinuria does not decrease by at least 50% after 4 to 8 weeks of maximum ACEi dose.
• Use combination therapy cautiously with close monitoring of blood pressure and renal function, as the risk of hypotension and acute kidney injury increases.

Professional Escalation Criteria for Complex Cases

While many cases of glomerular disease can be managed in general practice, certain situations warrant referral to a veterinary internist or nephrologist. The following criteria are based on consensus recommendations and clinical experience.

Referral is indicated when:

• UPC remains above 2.0 after 8 weeks of maximum antiproteinuric therapy with ACEi and ARB.
• Serum albumin remains below 2.0 g/dL despite adequate therapy.
• Creatinine increases by more than 1.0 mg/dL within 4 weeks of starting therapy.
• Systolic blood pressure remains above 160 mmHg despite three antihypertensive agents.
• Renal biopsy is needed but the clinician lacks experience or access to specialized pathology.
• The patient develops thromboembolic complications such as pulmonary thromboembolism or aortic thrombosis.
• The patient requires hemodialysis for acute kidney injury or refractory uremia.
• The owner requests a second opinion or advanced diagnostic testing.

Referral centers offer advanced diagnostic tools including renal biopsy with light microscopy, immunofluorescence, and electron microscopy, as well as genetic testing for hereditary nephropathies. They also have experience managing complex cases and can provide owner education and support. The World Organisation for Animal Health addresses animal health and welfare considerations for chronic disease management, including the importance of timely referral when indicated.

Limitations of the Decision Framework

This framework is based on published consensus recommendations and clinical experience, but it has limitations. Not all patients fit neatly into a single stage, and individual responses to therapy vary. The framework does not account for all possible underlying causes of glomerular disease, and some patients may require individualized approaches. The urinary biomarkers of kidney disease in dogs and cats, discussed in the Veterinary Clinics of North America, may eventually improve staging and monitoring, but their routine use is not yet established.

Clinicians should use this framework as a guide instead of a strict protocol. Clinical judgment, owner input, and patient-specific factors should always inform decision-making. When in doubt, consultation with a veterinary internist is recommended.

Practical Decision Framework for Managing Canine Glomerular Disease: A Stepwise Approach Based on Clinical Severity and Response

Managing canine glomerular disease requires a structured decision framework that accounts for disease severity, response to initial therapy, and the presence of complications. Without a systematic approach, clinicians may delay appropriate interventions or escalate therapy unnecessarily. This section provides a practical decision framework organized by clinical severity, a record system for tracking key parameters, troubleshooting methods for common management challenges, and a comparison of antiproteinuric drug classes to guide therapeutic choices.

Clinical Severity Staging and Corresponding Management Pathways

The first step in applying a decision framework is to stage the patient based on proteinuria severity, serum albumin concentration, and the presence of complications such as edema, ascites, or hypertension. The consensus recommendations for standard therapy of glomerular disease in dogs, published in the Journal of Veterinary Internal Medicine, provide a foundation for staging, though specific numeric thresholds for severity categories are not universally defined. The following framework uses commonly accepted clinical cutoffs derived from published consensus and clinical experience.

Stage 1: Mild Proteinuria (UPC 0.5 to 1.5, Normal Albumin, No Azotemia)

Patients in this stage have early glomerular disease without significant protein loss or renal dysfunction. The primary goal is to slow progression and prevent worsening of proteinuria.

Management steps:

1. Confirm persistent proteinuria with at least two UPC measurements 2 to 4 weeks apart, ruling out pre-renal and post-renal causes.
2. Measure blood pressure using Doppler or oscillometric methods. If systolic pressure exceeds 140 mmHg, initiate antihypertensive therapy.
3. Start an angiotensin-converting enzyme inhibitor (ACEi) such as enalapril at 0.5 mg/kg orally every 12 to 24 hours, or benazepril at 0.25 to 0.5 mg/kg orally every 24 hours. The Merck Veterinary Manual provides general dosing guidelines for these medications.
4. Recheck UPC, serum creatinine, and blood pressure 2 to 4 weeks after starting therapy.
5. If UPC decreases by less than 50% or remains above 0.5, consider increasing the ACEi dose to the maximum tolerated level, typically 1.0 mg/kg every 12 hours for enalapril.
6. If proteinuria persists despite maximum ACEi dose, add an angiotensin receptor blocker (ARB) such as telmisartan at 1.0 mg/kg orally every 24 hours. Monitor blood pressure closely for hypotension.

Dietary modification is recommended at this stage. Transition the patient to a commercial renal diet with moderate protein restriction, reduced phosphorus, and added omega-3 fatty acids. The management of proteinuria in dogs and cats with chronic kidney disease, reviewed in the Veterinary Clinics of North America, supports dietary intervention as part of a multimodal approach.

Stage 2: Moderate Proteinuria (UPC 1.5 to 3.5, Mild Hypoalbuminemia 2.0 to 2.5 g/dL, No Edema)

Patients in this stage have significant protein loss but have not yet developed nephrotic syndrome. The risk of progression to renal failure is higher, and more aggressive intervention is warranted.

Management steps:

1. Initiate ACEi therapy at standard doses and titrate to maximum tolerated dose within 2 to 4 weeks.
2. Add an ARB if proteinuria does not decrease by at least 50% or remains above 1.0 after ACEi optimization.
3. Measure blood pressure at each visit. If systolic pressure exceeds 150 mmHg despite ACEi and ARB, add amlodipine at 0.1 to 0.25 mg/kg orally every 24 hours, titrating up to 0.5 mg/kg as needed.
4. Consider renal biopsy if the underlying cause is uncertain or if immunosuppressive therapy is being considered. The consensus recommendations for the diagnostic investigation of dogs with suspected glomerular disease, published in the Journal of Veterinary Internal Medicine, outline indications for biopsy.
5. If biopsy reveals immune-mediated glomerulonephritis, discuss immunosuppressive therapy with the owner. The consensus recommendations for immunosuppressive treatment of dogs with glomerular disease based on established pathology, published in the Journal of Veterinary Internal Medicine, provide specific protocols.
6. Monitor serum albumin, UPC, creatinine, and blood pressure every 4 to 6 weeks until stable, then every 2 to 3 months.

Stage 3: Severe Proteinuria (UPC Greater than 3.5, Hypoalbuminemia Less than 2.0 g/dL, With or Without Edema or Ascites)

These patients have nephrotic syndrome or are at high risk of developing it. Hospitalization is often required for initial stabilization.

Management steps:

1. Hospitalize the patient for intravenous fluid therapy if dehydrated, but avoid overhydration. Use balanced crystalloid solutions at maintenance rates.
2. Start ACEi therapy at low doses (0.25 mg/kg every 12 to 24 hours) and titrate slowly to avoid hypotension. Monitor blood pressure and renal function daily.
3. Add an ARB if proteinuria does not improve within 1 to 2 weeks.
4. Manage edema with cautious diuretic therapy. Furosemide at 1 to 2 mg/kg intravenously or orally every 12 to 24 hours may be used, but monitor for worsening azotemia. The clinical features and evidence-based treatment considerations for nephrotic syndrome in dogs, discussed in Topics in Companion Animal Medicine, emphasize careful diuretic use.
5. Consider antithrombotic therapy. Low-dose aspirin at 0.5 to 1.0 mg/kg orally every 24 hours may reduce thromboembolic risk, though evidence is limited. Discuss risks and benefits with the owner.
6. Perform renal biopsy if the patient is stable and the diagnosis is uncertain. Biopsy is contraindicated in unstable patients or those with uncontrolled hypertension or coagulopathy.
7. If biopsy confirms immune-mediated disease, initiate immunosuppressive therapy as per consensus recommendations.
8. Monitor UPC, serum albumin, creatinine, and blood pressure daily during hospitalization, then weekly after discharge until stable.

Stage 4: End-Stage Kidney Disease (Azotemia with Creatinine Greater than 4.0 mg/dL, UPC Variable)

Patients with advanced renal failure have limited therapeutic options. The focus shifts to supportive care and quality of life.

Management steps:

1. Continue ACEi or ARB therapy if tolerated, but reduce doses if hypotension or worsening azotemia occurs.
2. Manage uremia with dietary protein restriction, phosphate binders, and antiemetics as needed.
3. Treat hypertension with amlodipine if ACEi or ARB are not tolerated.
4. Discuss prognosis with the owner. Median survival times are short, and euthanasia may be considered when quality of life declines.
5. Refer to a veterinary internist for consideration of hemodialysis if appropriate and available.

Record System for Tracking Key Parameters

A standardized record system is essential for monitoring disease progression and treatment response. The following table provides a template for tracking key parameters at each visit. This system allows the clinician to identify trends and adjust therapy promptly.

Instructions for use:

• Record UPC at each visit. A decrease of at least 50% from baseline or to below 0.5 indicates a good response.
• Serum albumin reflects the severity of protein loss. Improvement suggests effective antiproteinuric therapy.
• Creatinine and BUN monitor renal function. A sustained increase of more than 0.5 mg/dL in creatinine may indicate disease progression or adverse drug effects.
• Blood pressure should be measured using a standardized protocol. Multiple readings over several minutes are averaged.
• Medications and doses should be recorded to track changes and ensure compliance.
• Notes should include any adverse effects, owner concerns, or changes in clinical status.

Troubleshooting Methods for Common Management Challenges

Even with a structured framework, clinicians encounter challenges that require troubleshooting. The following methods address common failure patterns.

Challenge 1: Persistent Proteinuria Despite Maximum ACEi and ARB Therapy

If UPC remains above 0.5 or has not decreased by at least 50% after 4 to 8 weeks of maximum tolerated ACEi and ARB therapy, consider the following:

1. Verify owner compliance. Ask about missed doses or difficulty administering medications.
2. Recheck blood pressure. Uncontrolled hypertension can worsen proteinuria. If systolic pressure exceeds 140 mmHg, add amlodipine.
3. Rule out concurrent conditions that cause proteinuria, such as urinary tract infection, hyperadrenocorticism, or diabetes mellitus. Perform urine culture, ACTH stimulation test, or blood glucose measurement as indicated.
4. Consider dietary indiscretion. Some dogs on renal diets may still receive high-protein treats or table food. Review the diet history with the owner.
5. If all above are ruled out, consider renal biopsy to identify the specific glomerular lesion. Some forms of glomerulonephritis may require immunosuppressive therapy for adequate proteinuria reduction.

Challenge 2: Worsening Azotemia During ACEi or ARB Therapy

A rise in creatinine of more than 0.5 mg/dL within 2 to 4 weeks of starting ACEi or ARB therapy requires evaluation.

1. Assess hydration status. Dehydration from vomiting, diarrhea, or reduced water intake can worsen azotemia. Provide subcutaneous or intravenous fluids if needed.
2. Reduce the ACEi or ARB dose by 25% to 50% and recheck creatinine in 5 to 7 days.
3. If azotemia persists despite dose reduction, temporarily discontinue the drug and recheck creatinine in 3 to 5 days.
4. If creatinine returns to baseline after drug discontinuation, consider restarting at a lower dose or switching to the other drug class.
5. If azotemia does not improve after drug discontinuation, investigate other causes such as disease progression, urinary obstruction, or concurrent nephrotoxic drug use.

Challenge 3: Refractory Edema Despite Diuretic Therapy

Edema that does not resolve with furosemide at 2 mg/kg every 12 hours requires a systematic approach.

1. Assess dietary sodium intake. Commercial renal diets are low in sodium, but some owners may add salt to food. Review the diet history.
2. Increase furosemide dose to 3 to 4 mg/kg every 12 hours, but monitor for worsening azotemia and electrolyte imbalances.
3. Add spironolactone at 1 to 2 mg/kg orally every 12 hours. This potassium-sparing diuretic may provide additive effect. Monitor potassium levels closely.
4. If edema persists, consider hospitalization for intravenous furosemide infusion or addition of a thiazide diuretic such as hydrochlorothiazide.
5. Re-evaluate the underlying disease. Worsening glomerular disease may require more aggressive antiproteinuric or immunosuppressive therapy.

Challenge 4: Hypertension Refractory to ACEi, ARB, and Amlodipine

If systolic blood pressure remains above 150 mmHg despite maximum doses of three antihypertensive agents, consider the following:

1. Verify measurement technique. Use a properly sized cuff and allow the patient to acclimate to the environment. Repeat measurements over several visits.
2. Rule out secondary causes of hypertension such as hyperadrenocorticism, pheochromocytoma, or renal artery stenosis. Perform appropriate diagnostic tests.
3. Add a beta-blocker such as atenolol at 0.5 to 1.0 mg/kg orally every 12 to 24 hours, or a vasodilator such as hydralazine at 0.5 to 2.0 mg/kg orally every 12 hours.
4. Refer to a veterinary internist for advanced management. Refractory hypertension carries a high risk of target organ damage including retinopathy, encephalopathy, and cardiovascular events.

Comparison of Antiproteinuric Drug Classes

Choosing between ACEi and ARB, or using them in combination, requires understanding their differences. The following table compares these drug classes for use in canine glomerular disease.

Clinical decision points:

• Start with an ACEi as first-line therapy due to lower cost and extensive clinical experience.
• Switch to an ARB if the patient develops adverse effects to ACEi, such as cough or hyperkalemia.
• Add an ARB to ACEi if proteinuria does not decrease by at least 50% after 4 to 8 weeks of maximum ACEi dose.
• Use combination therapy cautiously with close monitoring of blood pressure and renal function, as the risk of hypotension and acute kidney injury increases.

Professional Escalation Criteria for Complex Cases

While many cases of glomerular disease can be managed in general practice, certain situations warrant referral to a veterinary internist or nephrologist. The following criteria are based on consensus recommendations and clinical experience.

Referral is indicated when:

• UPC remains above 2.0 after 8 weeks of maximum antiproteinuric therapy with ACEi and ARB.
• Serum albumin remains below 2.0 g/dL despite adequate therapy.
• Creatinine increases by more than 1.0 mg/dL within 4 weeks of starting therapy.
• Systolic blood pressure remains above 160 mmHg despite three antihypertensive agents.
• Renal biopsy is needed but the clinician lacks experience or access to specialized pathology.
• The patient develops thromboembolic complications such as pulmonary thromboembolism or aortic thrombosis.
• The patient requires hemodialysis for acute kidney injury or refractory uremia.
• The owner requests a second opinion or advanced diagnostic testing.

Referral centers offer advanced diagnostic tools including renal biopsy with light microscopy, immunofluorescence, and electron microscopy, as well as genetic testing for hereditary nephropathies. They also have experience managing complex cases and can provide owner education and support. The World Organisation for Animal Health addresses animal health and welfare considerations for chronic disease management, including the importance of timely referral when indicated.

Limitations of the Decision Framework

This framework is based on published consensus recommendations and clinical experience, but it has limitations. Not all patients fit neatly into a single stage, and individual responses to therapy vary. The framework does not account for all possible underlying causes of glomerular disease, and some patients may require individualized approaches. The urinary biomarkers of kidney disease in dogs and cats, discussed in the Veterinary Clinics of North America, may eventually improve staging and monitoring, but their routine use is not yet established.

Clinicians should use this framework as a guide instead of a strict protocol. Clinical judgment, owner input, and patient-specific factors should always inform decision-making. When in doubt, consultation with a veterinary internist is recommended.

Frequently Asked Questions

What is the difference between glomerular disease and chronic kidney disease in dogs?

Glomerular disease is a specific type of kidney disease that primarily affects the glomeruli, leading to proteinuria. Chronic kidney disease is a broader term that includes any progressive loss of kidney function, which may or may not involve glomerular damage. Glomerular disease can cause chronic kidney disease, but not all chronic kidney disease is glomerular in origin.

How is proteinuria quantified in dogs?

Proteinuria is quantified using the urine protein:creatinine ratio on a single urine sample. A UPC ratio greater than 0.5 is considered abnormal in dogs. The ratio corrects for urine concentration and provides a reliable estimate of daily protein loss. Serial measurements are used to monitor response to therapy.

When is a renal biopsy necessary for diagnosing glomerular disease?

A renal biopsy is necessary when the diagnosis remains unclear after non-invasive testing, or when histopathology is required to guide immunosuppressive therapy. It is also indicated when hereditary nephropathy is suspected. Biopsy is not recommended in unstable patients or when amyloidosis is strongly suspected.

What are the first-line medications for reducing proteinuria in dogs?

Angiotensin-converting enzyme inhibitors such as enalapril or benazepril are first-line agents. Angiotensin receptor blockers like telmisartan are alternatives. These drugs reduce glomerular capillary pressure and decrease proteinuria. The goal is to reduce the UPC ratio to below 0.5 or by at least 50% from baseline.

Can diet help manage glomerular disease in dogs?

Yes, dietary management is important. A diet with moderate protein restriction and supplemented with omega-3 fatty acids may reduce glomerular hypertension and inflammation. Phosphorus restriction is also beneficial if azotemia is present. Commercial renal diets are formulated with these principles in mind.

What is nephrotic syndrome in dogs?

Nephrotic syndrome is a severe form of glomerular disease characterized by heavy proteinuria, hypoalbuminemia, edema, and ascites. It requires aggressive management including diuretics, antiproteinuric therapy, and sometimes antithrombotic therapy. Hospitalization is often necessary due to the risk of complications.

What is the prognosis for a dog with glomerular disease?

Prognosis varies widely. Dogs with immune-mediated glomerulonephritis that responds to immunosuppression may have a good outcome. Dogs with amyloidosis or those that develop end-stage kidney disease have a poor prognosis. Regular monitoring and treatment adherence are critical for optimizing outcomes.

How often should a dog with glomerular disease be monitored?

Monitoring frequency depends on disease severity. Stable patients should be rechecked every 1 to 3 months with UPC, serum albumin, creatinine, BUN, and blood pressure. Unstable patients or those with nephrotic syndrome may require more frequent monitoring, sometimes weekly or biweekly.

Related Veterinary Guides

• Dog
• Dog Shedding Management
• How To Skin A Dog
• Dog Kidney Disease Diet
• Arthritis In Dogs Symptoms And Diagnosis

References and Further Reading

• www.merckvetmanual.com
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Consensus recommendations for standard therapy of glomerular disease in dogs.. Journal of veterinary internal medicine, 2013.
• Consensus recommendations for the diagnostic investigation of dogs with suspected glomerular disease.. Journal of veterinary internal medicine, 2013.
• Urinary Biomarkers of Kidney Disease in Dogs and Cats.. The Veterinary clinics of North America. Small animal practice, 2023.
• Management of Proteinuria in Dogs and Cats with Chronic Kidney Disease.. The Veterinary clinics of North America. Small animal practice, 2016.
• Consensus recommendations for immunosuppressive treatment of dogs with glomerular disease based on established pathology.. Journal of veterinary internal medicine, 2013.
• Nephrotic syndrome in dogs: clinical features and evidence-based treatment considerations.. Topics in companion animal medicine, 2011.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.